Jubak Picks
March 12, 2024 | Daily JAM, Jubak Picks, QCOM, Stock Alerts, Videos |
Today’s Quick Pick is Qualcomm, (QCOM). I always look for product momentum in technology stocks, and Qualcomm’s pipeline is very promising. The company reported a good first quarter for 2024 but I’m focused on growth for their Snapdragon chip which is used in cell phones, cars, and the internet of things. Qualcomm has recently renewed its chip agreements with Apple and Samsung. Samsung’s Galaxy 24 is the first cell phone to include AI technology powered by Snapdragon and sales are up 13% year over year from 2023 and 47% from 2024. It’s likely more companies will be looking to add AI to their phones and I think Qualcomm has a leading position in that market. A new Snapdragon product, X-Elite, will put AI on PCs and is coming out this year. In 2023 the Snapdragon chip was also installed in infotainment modules for 75 new car models and the company’s automotive revenue is up about 12% this quarter. The Internet of Things is growing more slowly but is still growing. Morningstar says the stock is trading at a 22% premium, but I find that to be very, very conservative. While this stock isn’t a bargain at the moment this is a decent time to get in on an AI stock with promising pipeline momentum, and I don’t see it being more reasonable any time soon. I added Qualcomm to my Jubak’s Picks Portfolio on January 15, 2024. The position is up 23.5% since then as of the close on March 12.
March 8, 2024 | Daily JAM, Jubak Picks, Mid Term |
Shares of Viking Therapeutics (VKTX) are down norther 6.22% as of noon today in New York. That comes after the stock dropped 18.84% yesterday. I think that the market thinking here by and large wrong and I’d use the big painful drop as an opportunity to buy more shares of Viking Therapeutics.
March 7, 2024 | Daily JAM, Jubak Picks, LLY, NVO |
Yes, I know this is my third post (plus video) on diabetes/weight-loss drug leader Novo Nordisk (NVO) in three weeks. But the company keeps pumping out research updates that keep powering the stock higher. Think of this as a momentum stock where the momentum comes from the R&D pipeline and not moves in the share price. (The last post was https://jubakam.com/another-reason-t…-success-for-glp/) Today, the company reported early results for a next-generation oral weight loss drug called amycretin, showing a 13.1% weight loss after 12 weeks. That’s a bigger weight-loss than either Novo Nordisk’s own Wegovy or Eli Lilly’s (LLY) competing drug Zepbound. Shares of Novo Nordisk were up 8.9% today to $135.85. I added them to my Jubak’s Picks Portfolio on February 20. The position is up 11.91% since then.
March 5, 2024 | Daily JAM, Jubak Picks, LLY, Morning Briefing, NVO, Volatility |
Back on February 20, I posted a video recommending a buy of Novo Nordisk (NVO). In the video, “Buy GLP-1,” I said that the stock, along with Eli Lilly (LLY) was riding the momentum of increased sales of GLP-1 drugs, originally developed to treat diabetes, as weight-loss drugs. Buy, I said, despite the huge run-up in the shares, because new trials and analysis of existing data were pointing to expanded uses for the drugs. Today, Novo Nordic announced exactly the kind of news that I had talked about.
February 29, 2024 | Daily JAM, Jubak Picks, Videos, Volatility |
Today’s Hot Button Moves NOW video is Buy Viking Therapeutics (VKTX). Last week I suggested that you buy GLP-1 drug stocks like Eli Lilly (LLY) or Novo Nordisk (NVO). This class of diabetes and weight loss drugs is growing rapidly, with $36.5 billion in sales in 2023. Viking Therapeutics, a development-stage biotech company, recently announced Phase 2 trial results for its compound VK2735. This drug has the potential to be the best in its class when it hits the market. The company still has to go through Phase 3 trials and approval, but the data show VK2735 to be more effective at weight loss than its competitors. It could also be one of the few drugs of its kind to be available orally. The current round of trials shows that the drug will need to be injected less frequently than competitors. The company trades with a market cap of $9 billion (in contrast to Lilly’s $720 billion market cap) and is still small enough that it could be bought before the expensive process of taking a drug to market. (Although the company recently raised a secondary offering that would advance marketing plans.) I would buy this up to $100 a share and expect it to continue to zoom as more good news, I expect, on the oral version gets released this quarter. I am adding the stock to my online portfolios today, Thursday, February 29. You can find a write up on this pick on my subscription JubakAM.com and free JubakPicks.com sites.
February 28, 2024 | Daily JAM, Jubak Picks, LLY, Stock Alerts, Volatility |
Yesterday, February 28, development-stage biotech Viking Therapeutics (VKTX) announced results from a Phase 2 training of its GLP-1 weight-loss drug candidate that that showed the potential for the VK2735 compound two move to be best in class in the $36.5 billion (revenue) market for GLP diabetes-control and weight-loss drugs. I will add Viking Therapeutic to my Volatility Portfolio and to my Jubak’s Picks Portfolio today, February 29, with a target price of $150.
February 21, 2024 | Daily JAM, Jubak Picks, Long Term, Millennial, PANW, Top 50 Stocks, Volatility |
After yesterday’s earnings report–the company beat Wall Street estimates for the quarter–and radically lower guidance for next quarter and the rest of 2024–total billings for next quarter will grow by just 2% to 4% and revenue for all of 2024 will grow by just 15% to 16% from 2023–shares of Palo Alto Networks (PANW) took a big hit right between the eyes. The stock fell 28.44% at the close and lost $104.12 a share to $261.97. What do I recommend? I’d say “buy” with a couple of caveats. Why buy?
February 20, 2024 | Daily JAM, Jubak Picks, LLY, Videos |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
February 20, 2024 | Daily JAM, Jubak Picks, Long Term, Morning Briefing |
t should be a familiar story in this priced-to-perfection market: Company beats big in current quarter but lowers guidance and stock takes a dive. Latest victim? Palo Alto Networks (PANW). The stock is down 14.09% at 4:30 New York time today. And with Nvidia scheduled to report tomorrow after the close, you can bet the market will be on edge tomorrow.
February 14, 2024 | Daily JAM, Jubak Picks, Stock Alerts, Top 50 Stocks, VWDRY |
My 10 Penny Stock Homeruns Pick #5: Vestas Wind Systems (VWDRY).
Technically, the Vestas Wind Systems ADR (VWDRY) isn’t a penny stock. By the strict definition, a penny stock sells for $5 or less and the Vestas ADR closed on $9.06 today, February 14. But I included Vestas in my previous penny stock list back on July 11, 2022, even though the stock closed at $7.80 that day. With the company reporting a return to profitability for 2023 in its fourth quarter earnings report released today, I think Vestas has (finally) turned the corner. And, frankly, I just don’t want drop it from this list just as things get good again for the company and its investors. (Vestas is a member of my Jubak’s Picks Portfolio. The position is up 65.6% since initiation on March 4, 2019.) Tomorrow, February 15, I’ll also add Vestas to my long-term 50 Stocks Portfolio.
February 3, 2024 | ALB, Daily JAM, Jubak Picks, Stock Alerts, Top 50 Stocks, Volatility |
This one is very simple. When the price of lithium rebounds, high-quality low-cost lithium producers will see the revenue roll in. That’s why I’d got the world’s leading lithium-producer Albemarle (ALB) in my long-term 50 Stock Portfolio. But a smaller, high-quality, low-cost producer like Australia’s Pilbara Minerals will show gains even higher than Albemarle since the current price of $2.29 a share comes close to discounting the company’s survival.
February 1, 2024 | Daily JAM, Jubak Picks, MSFT, Top 50 Stocks, Videos |
Today’s video is Microsoft Shows Priced to Perfection Risks. This quarter, the company reported Tuesday, Azure, its cloud services flagship, grew revenue by 30% last year. While a 30% growth rate would be a great for many companies, Wall Street and analysts were disappointed in this news from Microsoft. This is the “priced to perfection” problem. Although the company beat earnings estimates, beat revenue estimates, and showed 30% growth in a key part of the company, the stock went down. Maybe a $3 trillion market cap on Microsoft is a lot of weight to push up hill. We could see more of this during this earnings season as Amazon, Apple and Meta release their own reports. The “Magnificent Seven” that were responsible for most of the 24% gain in the S&P in 2023 are beginning to wobble. My hope was for more market leaders to emerge but that doesn’t seem to be happening. I don’t expect “wobble” to cause anything that terrible in the market, but a sideways move is likely as investors ponder their next move.
